Therapeutics News

Stopping glaucoma medication resulted in a dose-dependent IOP increase in patients treated for open-angle glaucoma, according to data from two independent clinical trial cohorts.

About a year ago I wrote a piece on hydroxychloroquine retinal toxicity, in which I explored the drug’s mechanism and why it yields its characteristic bullseye.

ATLANTA – Eyevance announced the U.S. launch of Zerviate, indicated for treating ocular itching associated with allergic conjunctivitis.

ATLANTA — A presenter at SECO said that emerging contact lens technology could release medication or assist patients with low vision.

Patients with dry eye disease should be educated about managing their disease to make treatment more successful, according to a review of dry eye disease treatment published in Clinical Ophthalmology.

ATLANTA – Eyenovia is evaluating atropine for progressive myopia and pilocarpine for presbyopia in several studies using the company’s Optejet microdose dispenser.

Data from a literature review showed that low-concentration atropine was effective in myopia control and may help prevent myopia progression in high-risk children.

Researchers found that patients who more consistently took their prescribed glaucoma medication were less likely to develop vision loss due to glaucoma.

Eye care providers should monitor glaucoma medication compliance in their patients who have cancer, researchers concluded in a study published in the American Journal of Ophthalmology.

Several physicians who spoke with Healio Primary Care applauded the FDA’s decision to make Pataday Twice Daily Relief and Pataday Once Daily Relief available over the counter to patients 2 years of age and older with itchy eyes associated with allergic conjunctivitis.